HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Acadesine, an adenosine-regulating agent with the potential for widespread indications.

AbstractBACKGROUND:
Acadesine is an adenosine-regulating agent that increases bioavailability of adenosine and has important metabolic effects, partly through activation of the key metabolic regulatory enzyme, AMP-activated protein kinase.
OBJECTIVE:
This review aimed to summarise and critique available data on the mechanism of action and clinical utility of acadesine, with a focus on treatment of ischaemic reperfusion injury, B-cell chronic lymphocytic leukaemia and diabetes mellitus.
METHODS:
The literature was acquired through numerous avenues including Medline, Pubmed, institutional libraries and relevant pharmaceutical companies using keyword search criteria for all trade and common names of acadesine and its derivatives.
RESULTS:
Acadesine has proven intravenous efficacy in the amelioration of ischaemic reperfusion injury associated with coronary artery bypass graft surgery in Phase III clinical trials. Acadesine is active only in metabolically stressed tissues in the presence of ATP catabolism and therefore has fewer unwanted peripheral side effects than systemic administration of adenosine. Metabolism of the drug is through the endogenous purine pathway and acadesine has been proven to be safe and well tolerated. More recently, acadesine has entered Phase I trials for B-cell chronic lymphocytic leukaemia to compete with purine antagonists that are used at present. AMPK-activating agents with high oral bioavailability have potential application in impaired glucose tolerance, insulin resistance and types 1 and 2 diabetes, however the poor oral bioavailability of acadesine precludes such application.
CONCLUSIONS:
This review highlights that, although limited to intravenous application, acadesine is a potentially viable therapy for ischaemic reperfusion injury following coronary artery bypass surgery. Further studies are required to determine the efficacy of acadesine for other ischaemic indications, including during percutaneous transluminal coronary angioplasty for acute myocardial infarction.
AuthorsBrian G Drew, Bronwyn A Kingwell
JournalExpert opinion on pharmacotherapy (Expert Opin Pharmacother) Vol. 9 Issue 12 Pg. 2137-44 (Aug 2008) ISSN: 1744-7666 [Electronic] England
PMID18671468 (Publication Type: Journal Article, Review)
Chemical References
  • Ribonucleosides
  • Aminoimidazole Carboxamide
  • acadesine
  • Adenosine
Topics
  • Adenosine (metabolism)
  • Aminoimidazole Carboxamide (administration & dosage, analogs & derivatives, pharmacology, therapeutic use)
  • Coronary Artery Bypass
  • Diabetes Mellitus (drug therapy)
  • Humans
  • Infusions, Intravenous
  • Leukemia, Lymphocytic, Chronic, B-Cell (drug therapy)
  • Myocardial Reperfusion Injury (metabolism, prevention & control)
  • Ribonucleosides (administration & dosage, pharmacology, therapeutic use)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: